Pheng L H, Perron A, Quirion R, Cadieux A, Fauchère J L, Dumont Y, Regoli D
Department of Pharmacology, Medical School, Université de Sherbrooke, Quebec, Canada.
Eur J Pharmacol. 1999 Jun 11;374(1):85-91. doi: 10.1016/s0014-2999(99)00296-4.
Ascending and descending segments of the rat colon were studied to analyze their contractile responses to neuropeptide Y and related peptides. These responses are (a) completely eliminated by tetrodotoxin (1 microM), (b) reduced to a variable extent (20 to 60%) by atropine (1 microM) and (c) not modified by indomethacin, diphenhydramine or methysergide. The order of potency of agonists for peptides related to neuropeptide Y was as follows: human pancreatic polypeptide = rat pancreatic polypeptide > peptide YY = peptide YY-(3-36) = [Leu31,Pro34]neuropeptide Y > neuropeptide Y-(2-36) > C2-neuropeptide Y = neuropeptide Y > neuropeptide Y-(13-36), with minor differences observed between the two parts of the colon. This selectivity pattern does not correspond to the profile of any known cloned neuropeptide Y receptors. BIBP3226, a selective antagonist for the neuropeptide Y Y1 receptor sub-type, was found to be inactive, while a neuropeptide Y Y2 receptor antagonist, T4-[NPY-(33-36)]4, reduced the effects of neuropeptide Y, peptide YY, peptide YY-(3-36) and C2-neuropeptide Y without affecting those of human pancreatic polypeptide, rat pancreatic polypeptide and [Leu31,Pro34]neuropeptide Y. JCF 104 (compound 28), a putative neuropeptide Y Y5 receptor antagonist, showed no effect or a weak inhibition of human pancreatic polypeptide or [Leu31,Pro34]neuropeptide Y-induced contraction. Taken together, these data suggest that: (1) at least two neuropeptide Y receptor types are present in the rat colon autonomic nerve terminals and modulate the release of acetylcholine and possibly other transmitters; (2) a proportion of the receptors mediating the contractile response of the rat colon (especially descending part) to neuropeptide Y and related peptides appears to be of the Y2 type and (3) the significant portion of the response is mediated by a receptor which is insensitive to neuropeptide Y Y1, Y2 and to neuropeptide Y Y5 receptor antagonists. This receptor behaves as a neuropeptide Y Y4 receptor sub-type and appears to be located on enteric nerves.
研究大鼠结肠的升段和降段,以分析它们对神经肽Y及相关肽的收缩反应。这些反应具有以下特点:(a) 被河豚毒素(1微摩尔)完全消除;(b) 被阿托品(1微摩尔)不同程度地减弱(20%至60%);(c) 不受吲哚美辛、苯海拉明或甲基麦角新碱影响。与神经肽Y相关的肽类激动剂的效力顺序如下:人胰多肽 = 大鼠胰多肽 > 肽YY = 肽YY-(3-36) = [亮氨酸31,脯氨酸34]神经肽Y > 神经肽Y-(2-36) > C2-神经肽Y = 神经肽Y > 神经肽Y-(13-36),结肠的两个部分之间观察到细微差异。这种选择性模式与任何已知的克隆神经肽Y受体的特征均不相符。发现神经肽Y Y1受体亚型的选择性拮抗剂BIBP3226无活性,而神经肽Y Y2受体拮抗剂T4-[NPY-(33-36)]4可减弱神经肽Y、肽YY、肽YY-(3-36)和C2-神经肽Y的作用,但不影响人胰多肽、大鼠胰多肽和[亮氨酸31,脯氨酸34]神经肽Y的作用。假定的神经肽Y Y5受体拮抗剂JCF 104(化合物28)对人胰多肽或[亮氨酸31,脯氨酸34]神经肽Y诱导的收缩无作用或仅有微弱抑制作用。综上所述,这些数据表明:(1) 大鼠结肠自主神经末梢中至少存在两种神经肽Y受体类型,调节乙酰胆碱及可能其他递质的释放;(2) 介导大鼠结肠(尤其是降段)对神经肽Y及相关肽收缩反应的一部分受体似乎是Y2型;(3) 该反应的很大一部分由对神经肽Y Y1、Y2及神经肽Y Y5受体拮抗剂不敏感的受体介导。这种受体表现为神经肽Y Y4受体亚型,似乎位于肠神经上。